Literature DB >> 3495451

Harmala alkaloids and related beta-carbolines: a myoclonic model and antimyoclonic drugs.

M R Pranzatelli, S R Snodgrass.   

Abstract

The neuropharmacologic profile of intraperitoneally injected harmala alkaloids and related beta-carbolines was evaluated in the rat. All drugs induced central effects (convulsions, catalepsy, or altered startle), but only harmaline and harmine were tremorogenic at low doses. Methoxylation of the carboline 7 position was requisite for this effect. Coadministration of harmaline (but not harmine) and 5-hydroxytryptophan (tryptamine or m-chlorophenyl-piperazine) induced a lethal convulsive myoclonic syndrome which could not be evoked by either drug separately. Compared with the myoclonic-serotonergic syndrome evoked by 5-hydroxytryptophan in rats with 5.7-dihydroxytryptamine lesions, harmaline+5-hydroxytryptophan-treated rats displayed more continuous and greater axial myoclonic jerks and some postural differences. Clorgyline or tranylcypromine but not pargyline could be substituted for harmaline. The harmaline syndrome was blocked by the benzodiazepine agonists, physostigmine and verapamil. The harmaline+5-hydroxytryptophan syndrome was blocked by drugs acting at benzodiazepine receptors (CL 218,872 greater than ethyl-beta-carboline-3-carboxylate, clonazepam, diazepam, Ro 15-1788, pentobarbital), and baclofen. Naloxone, benztropine, quipazine, and apomorphine had partial effects, and calcium channel blockers prevented death but did not prevent convulsions. 5-Hydroxytryptamine antagonists were poor blockers, although cyproheptadine and ketanserin significantly reduced mortality. Phenobarbital was more effective than other anticonvulsants. Lesion studies suggested a role for monoaminergic neurons and the inferior olive in the expression of the harmaline+5-hydroxytryptophan syndrome. These data describe a complex convulsive myoclonic syndrome that is behaviorally related to but pharmacologically distinct from the serotonin syndrome, which may be useful in studying serotonergic-benzodiazepine interactions in the pathophysiology of myoclonus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495451     DOI: 10.1016/0014-4886(87)90231-7

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

2.  Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor.

Authors:  Arnulfo Quesada; Peter H Bui; Gregg E Homanics; Oliver Hankinson; Adrian Handforth
Journal:  Eur J Pharmacol       Date:  2011-01-21       Impact factor: 4.432

3.  The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor.

Authors:  C M Sinton; B I Krosser; K D Walton; R R Llinás
Journal:  Pflugers Arch       Date:  1989-05       Impact factor: 3.657

4.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

5.  Development of Harmaline-induced Tremor in a Swine Model.

Authors:  Jihyun Lee; Inyong Kim; Jeyeon Lee; Emily Knight; Lei Cheng; Shin Il Kang; Dong Pyo Jang; Su-Youne Chang
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-03-13

Review 6.  Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.

Authors:  Helin Atas-Ozcan; Véronique Brault; Arnaud Duchon; Yann Herault
Journal:  Genes (Basel)       Date:  2021-11-20       Impact factor: 4.096

7.  Peganum harmala intoxication, a case report.

Authors:  Mohammad Moshiri; Leila Etemad; Soheila Javidi; Anahita Alizadeh
Journal:  Avicenna J Phytomed       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.